


**Product Name** : TD-1473  
**Cat. No.** : PC-72341  
**CAS No.** : 2051918-33-1  
**Molecular Formula** : C<sub>22</sub>H<sub>26</sub>N<sub>8</sub>  
**Molecular Weight** : 402.506  
**Target** : JAK  
**Solubility** : 10 mM in DMSO



## Biological Activity

TD-1473 (Izencitinib, TD1473, JNJ 8398) is a potent, selective, oral gut-selective **pan-JAK** inhibitor with pKi of 10.0/10.0/8.8/9.5 for human recombinant JAK1, JAK2, JAK3 and TYK2.

TD-1473 inhibited cytokine-induced phosphorylation of STAT1 in mouse primary colonic epithelial cells with pIC50 values for inhibition against IL-6, IFN $\alpha$  and IFN $\gamma$  were 7.3, 6.8 and 7.0.

TD-1473 demonstrated JAK inhibitory activity in ex vivo mouse colon and human IBD patient colonic tissue.

TD-1473 (Izencitinib) is under development for the treatment of ulcerative colitis.

## References

Sandborn WJ, et al. *J Crohns Colitis*. 2020 Sep 16;14(9):1202-1213.

Hardwick RN, et al. *Toxicol Sci*. 2022 Feb 4:kfac002.

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com